Ironwood Pharmaceuticals has announced that Michael Shetzline will join Ironwood as chief medical officer, senior vice president and head of drug development, effective January 28, 2019. Shetzline will lead global product development for Ironwood following its planned separation into two independent, publicly-traded companies. In his role, Shetzline will focus on driving innovation designed to enhance the value of the company’s existing GI assets and creating new GI product opportunities. He will report to Thomas McCourt, who will become President of Ironwood following the separation.